Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company based in Conshohocken, Pennsylvania, dedicated to developing innovative therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with a high unmet medical need. Their lead clinical candidate, resmetirom, is currently undergoing studies for the treatment of patients with NASH and significant liver fibrosis.
With a focus on improving care for patients with NASH, Madrigal Pharmaceuticals is committed to advancing novel treatments for this challenging liver disease. Despite the lack of FDA-approved options for NASH, the company's efforts aim to address the significant clinical impact of the condition and provide hope for those affected by it.
Generated from the website